Brightine for Cholangiocarcinoma and Pancreatic Cancers

By |2023-06-27T02:50:20+10:00June 26th, 2023|Posts, The Empowered patient|

Boehringer Ingelheim is studying BI 907828, an investigational MDM2-p53 antagonist, for advanced biliary tract or pancreatic cancer.